ReviewDrug design, development and therapy2013
Molecularly targeted drugs for metastatic colorectal cancer.
Review in Drug design, development and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.Retina (Philadelphia, Pa.) · 2017Trial
- Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.The oncologist · 2023Review
- VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.Annals of medicine · 2022Review
- The novel FGFR inhibitor F1-7 induces DNA damage and cell death in colon cells.British journal of cancer · 2022Article
- Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments.Pharmaceutics · 2021Review
- RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.BMC cancer · 2021Article
- The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy.Oncotarget · 2021Article
- Treatment With Medicinal Mushroom Extract Mixture Inhibits Translation and Reprograms Metabolism in Advanced Colorectal Cancer Animal Model as Evidenced by Tandem Mass Tags Proteomics Analysis.Frontiers in pharmacology · 2020Article
- Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding.International journal of retina and vitreous · 2018Article
- The efficacy and safety of aflibercept and conbercept in diabetic macular edema.Drug design, development and therapy · 2018Review
- PersonalizedCancer discovery · 2017Article
- Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.Journal of experimental & clinical cancer research : CR · 2017Article
- Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism.Oncology letters · 2017Article
- Wnt-β-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer.Cancer science · 2016Article
- Article
- Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept.International journal of retina and vitreous · 2016Review
- Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer.Radiation oncology journal · 2015Article
- A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.BMC cancer · 2015Article
- Construction of interference vector targeting Ep-CAM gene and its effects on colorectal cancer cell proliferation.Drug design, development and therapy · 2015Article
- FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer.Cancer biology & therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The survival rate of patients with metastatic colorectal cancer (mCRC) has significantly improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a substantial improvement in the overall survival rate. These drugs are capable of specifically targeting the inherent abnormal pathways in cancer cells, which are potentially less toxic than traditional nonselective chemotherapeutics. In this review, the recent clinical information about molecularly targeted therapy for mCRC is summarized, with specific focus on several of the US Food and Drug Administration-approved molecularly targeted drugs for the treatment of mCRC in the clinic. Progression-free and overall survival in patients with mCRC was improved greatly by the addition of bevacizumab and/or cetuximab to standard chemotherapy, in either first- or second-line treatment. Aflibercept has been used in combination with folinic acid (leucovorin)-fluorouracil-irinotecan (FOLFIRI) chemotherapy in mCRC patients and among patients with mCRC with wild-type KRAS, the outcomes were significantly improved by panitumumab in combination with folinic acid (leucovorin)-fluorouracil-oxaliplatin (FOLFOX) or FOLFIRI. Because of the new preliminary studies, it has been recommended that regorafenib be used with FOLFOX or FOLFIRI as first- or second-line treatment of mCRC chemotherapy. In summary, an era of new opportunities has been opened for treatment of mCRC and/or other malignancies, resulting from the discovery of new selective targeting drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.